# Nasus Pharma Ltd (NSRX)

- Sector: Healthcare · Industry: Drug Manufacturers General
- SEC CIK: 0002029039 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002029039))
- Full page: https://inspectstocks.com/stocks/nsrx
- Data as of: price 2026-09-28; newest filing used 2026-03-25; latest fiscal period ended 2025-12-31

## Grade

**F-** on the balance-sheet rubric used for lenders, 0 of 4 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -$5.9M |  |
| Earnings growing overall | failed | -$5.9M | -$1.1M |
| Earnings growing recently | failed | -$5.9M | -$1.5M |
| Earns well on its assets | failed | -117.0% |  |
| Book value per share growing | not answerable | $0.35 |  |

Business quality (the + / − mark): 1 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -0.5% |  |
| Healthy profit margin | failed | -0.5% |  |
| Strong operating margin | failed | -0.4% |  |
| Good return on equity | failed | -211.6% |  |
| Debt under control | passed | 0.04 |  |
| Turns sales into cash | failed | -0.4% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $1.2B |
| Net income, trailing twelve months | -$5.9M |
| Free cash flow, trailing twelve months | -$4.9M |
| Net margin | -0.5% |
| Operating margin | -0.4% |
| Return on equity | -211.6% |
| Debt to equity | 0.04 |
| Diluted EPS, trailing twelve months | -$0.72 |
| Share price | $3.39 |
| Market value | $30.6M |
| Price / sales | 0.0x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/nsrx)
- [Financial statements](https://inspectstocks.com/stocks/nsrx/financials)
- [Competitors](https://inspectstocks.com/stocks/nsrx/peers)
- [Earnings](https://inspectstocks.com/stocks/nsrx/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.